Improved antidotes for nerve agent and pesticide poisoning
Official title: Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning
Funded at Mississippi State University · NIH-11162250 · Data updated 2026-11-12
New antidote medications are being developed to save lives and protect the brain for people exposed to organophosphate nerve agents or pesticides.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mississippi State University NIH-funded |
| Lab location | 1 site (Mississippi State, United States) |
| Project start | August 1, 2021 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $641,224 |
| NIH project number | 5U01NS123255-05 |
| Project ID | NIH-11162250 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who have acute organophosphate poisoning from nerve agents or pesticides, or those at high risk of such exposure (e.g., certain military personnel or first responders), would be the eventual candidates for this treatment.
✕Less likely to help
People with poisonings from non-organophosphate chemicals or chronic illnesses unrelated to acetylcholinesterase inhibition are unlikely to benefit from this antidote.
What this research studies
This project works to create a better antidote than the common drug 2-PAM, especially one that reaches and protects the brain. Researchers have designed and tested a series of substituted phenoxyalkyl pyridinium oximes that improved survival and reduced seizure-like behavior and brain injury in rats and showed limited success in guinea pigs. The team is advancing a lead compound (Oxime 20) and optimizing formulation, dosing, and safety in animal models so the drug can move toward human testing. The goal is to build the data needed to support future clinical trials and emergency use if approved.
Why it matters
Potential benefit: Could offer a more effective emergency antidote that both saves lives and reduces brain damage after organophosphate exposure.
How similar studies have gone: Preclinical animal studies have shown better survival and reduced seizure and neuropathology compared with the standard antidote 2-PAM, but human trials have not yet been done.
Where this research is happening
-
Mississippi State University
Mississippi State, United States Active
Researchers
- Principal investigator: Chambers, Janice Elaine — Mississippi State University
- Study coordinator: Chambers, Janice Elaine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.